First preparation and unique advanced lung cancer patients or a simplified ALK Positive NSCLC

The FDA approved the use Bksalkori (XALKORI) Pfizer's first and only product of its kind in lung cancer patients with advanced or metastatic NSCLC type ALK Positive.Approval is the first in six years a new drug can be designed to treat lung cancer.The Food and Drug Administration (FDA) approved the drug Ksalkori (Krizotinib), of Pfizer, to treat patients with advanced lung cancer or metastatic